Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Injectable Aesthetics
    • Dermatological Skincare
    • Therapeutic Dermatology
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2024
    • The aesthetic impact of medication-driven weight loss
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Podcasts
  • Innovation
    • Skin Science by Galderma
    • Bringing innovation to life
    • Partnering
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • For society
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Home
  • Investors

AMWC 2023: Data from Galderma's broad aesthetic portfolio

News story

AAD 2023: Extensive updates from Galderma’s broad and innovative portfolio through posters and presentation sessions

News story

Galderma, the pure-play dermatology category leader and maker of Cetaphil, celebrates grand opening of U.S. headquarters in Dallas

News story

Sales data confirm Galderma’s range of anti-acne products is the No.1 choice globally

News story

Galderma expands with new production site in Uppsala, Sweden

News story

Galderma study paves the way for an effective, new acne treatment combination

News story

Actinic Keratosis prevention campaign encourages everyone to ‘FACE THE FACTS’

News story

Pagination

  • Previous page Previous Page
Subscribe to News story
  1. Home
  2. News story

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2025

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back